Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
Acquired by Bristol-Myers Squibb
|
| gptkbp:awards |
Best Places to Work
Innovative Company Award |
| gptkbp:ceo |
gptkb:Charles_M._Baum
|
| gptkbp:clinical_trial |
combination therapies
Phase 1 trials Phase 2 trials monotherapy studies KRAS G12 C inhibitors |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:community_engagement |
gptkb:healthcare_professionals
gptkb:scientific_community patient advocacy |
| gptkbp:employees |
over 200
|
| gptkbp:financials |
publicly traded
revenue growth investment funding |
| gptkbp:focus |
genetic and epigenetic drivers of cancer
|
| gptkbp:founded |
gptkb:2010
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirati Therapeutics
|
| gptkbp:instruction_set |
targeted therapies
immunotherapies |
| gptkbp:investment |
Venture capital firms
|
| gptkbp:leadership |
executive team
scientific advisory board |
| gptkbp:mission |
transforming the lives of patients
|
| gptkbp:partnerships |
Collaboration with Astra Zeneca
Collaboration with Merck |
| gptkbp:products |
gptkb:Adagrasib
Krazati |
| gptkbp:research |
molecular biology
drug discovery clinical development |
| gptkbp:research_areas |
solid tumors
hematologic malignancies |
| gptkbp:research_focus |
oncology
|
| gptkbp:stock_symbol |
MRTX
|
| gptkbp:technology |
biomarker discovery
genomic sequencing precision medicine |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:values |
gptkb:collaboration
gptkb:accountability innovation integrity excellence |
| gptkbp:vision |
leading in targeted therapies
|
| gptkbp:website |
www.miratitherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
gptkb:Hikma_Pharmaceuticals |
| gptkbp:bfsLayer |
5
|